Merck KGaA shortens list of bidders for drug unit

The Economic Times is reporting that Stada Arzneimittel and Barr Pharmaceuticals failed to make the first cut in the closely watched bidding war for Merck KGaA's generic drug business. Ranbaxy, Teva, Actavis and Mylan Laboratories evidently all made the short list of suitors. Analysts expect the drug unit to go for more than $6 billion.

- here's the AFX report for more information

ALSO: Any biotech knockoffs approved by the FDA would only be considered "similar" to approved biologics, says the FDA commissioner, and could not be used interchangeably. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.